Literature DB >> 32792439

Productivity losses among people with back pain and among population-based references: a register-based study in Sweden.

Filip Gedin1, Kristina Alexanderson2, Niklas Zethraeus3, Korinna Karampampa2.   

Abstract

OBJECTIVE: Back pain is the leading cause for years lived with disability globally and among the main reasons for sickness absence (SA) and disability pension (DP). The objective of this study was to explore the occurrence of SA and DP and to estimate productivity losses among individuals with back pain compared with among matched population-based references.
DESIGN: Explorative prospective cohort study using register microdata. PARTICIPANTS AND
SETTING: A total of 23 176 people, aged 19-60 years, with a first visit to inpatient or specialised outpatient healthcare for back pain (International Statistical Classification of Diseases and Related Health Problems code M54) in 2010 in Sweden and a matched population-based reference group (n=115 880). OUTCOMES: Long-term SA (in SA spells >14 days) and DP and productivity losses, measured in € (2018 prices) by multiplying the SA and DP net days by the societal cost of each such day.
RESULTS: In the back-pain group, 42% had SA or DP days; in the reference group, the corresponding proportion was 15%. Productivity loss per patient with back pain was €8928 during the 12-month follow-up period; in the reference group, it was €3499 (p<0.0001).
CONCLUSIONS: SA and DP, leading to excess productivity losses among people with back pain, reflect the challenges these patients are facing to maintain their work capacity. Interventions to promote that individuals with back pain remain in paid work should be a priority in order to address the high costs. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  back pain; health economics; pain management

Mesh:

Year:  2020        PMID: 32792439      PMCID: PMC7430424          DOI: 10.1136/bmjopen-2019-036638

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


Use of high-quality data from nationwide administrative registers covering all working aged individuals with incident specialised outpatient or inpatient healthcare for back pain (n=23 176) in an entire country; that is: no selection, no drop-outs and no self-reported data. A prospective population-based cohort study design. Use of a matched reference group five times the size of the studied population (n=115 880). Information about the first 14 days of sickness absence spells could not be included, meaning that the costs may be somewhat underestimated.

Introduction

Today, back pain is one of the major public health problems among individuals of working age.1 The prevalence of back pain varies between 15% and 30% in different populations2 3 and the majority of adults will experience back pain at some point in their life.4 Low back pain is the most common type of back pain, with a lifetime prevalence of 84%.5 Back pain is a leading cause of years lived with disability (YLD),6 7 estimated as the prevalence of back pain multiplied by a disability weight reflecting any short-term or long-term loss in health.8 The YLDs due to back pain have increased by 54% since the 1990s, and were estimated at 60 million YLDs in 2015.9 Due to back pain, an individual’s work capacity can be affected; in fact, back pain is ranked among the most frequent causes of short-term or permanent marginalisation from the labour market in terms of sickness absence (SA) and disability pension (DP).10 Chronic back pain (pain persisting more than 3 months) is often associated with productivity losses due to SA,11 12 as well as a higher risk of being granted DP.13–15 The societal costs of low back pain, that is, all healthcare costs and productivity losses associated with the disease, were estimated at €1860 million in Sweden in 2001, with SA being the main cost driver. Among patients who were employed, 60% had at least 1 day of SA due to low back pain during a 3-month period.16 17According to the Swedish Social Insurance Agency, back pain was one of two diagnoses accounting for the largest proportion of total SA benefits (7%) in 2011.18 There is a need to both update and expand our knowledge regarding SA, DP and productivity losses among people with back pain. In addition, no information is available showing the association of these three outcomes with multimorbidity, that is, individuals diagnosed with back pain also having other medical conditions. The aim of this study was to explore the occurrence of SA and DP, and to estimate productivity losses among individuals with back pain compared with among matched references.

Methods

A population-based explorative prospective cohort study was conducted, using microdata from four Swedish nationwide administrative registers, of people having had specialised outpatient or inpatient healthcare due to back pain. Data in the registers were linked using the unique personal identity numbers that all residents in Sweden have.19 The inclusion criteria for the back-pain group were: Aged 19–60 years in 2010, having lived in Sweden in 2005–2009. Having been diagnosed with back pain (International Statistical Classification of Diseases and Related Health Problems (ICD-10) code M54)20 as main diagnosis in inpatient or specialised outpatient healthcare in 2010. No previous inpatient or specialised outpatient healthcare for back pain as main or secondary diagnosis according to the National Patient Register (available since 1987 for inpatient healthcare and since 2001 for specialised outpatient healthcare). A matched reference group was drawn from the general population in Sweden among all those who in 2010 were 19–60 years, had lived in Sweden in 2005–2009 and had no previous, current or in the 12 following month a main or secondary diagnoses of back pain (ICD-10 code M54) according to the National Patient Register. For each identified individual with back pain, five references were included, matched with regard to sex, age, type of living area and country of birth. The four nationwide registers used were administrated by the following three authorities: Statistics Sweden: Longitudinal Integration Database for Health Insurance and Labour Market Studies, for information on age, sex (female/male), type of living area (big cities/medium-sized cities/rural areas), country of birth (Sweden/Nordic countries except Sweden/EU25 except Nordic countries/rest of the world), educational level (elementary school/high school/university or college), occupation (white collar/blue collar/missing) and family situation (married or cohabitating without children at home/married or cohabitating with children at home/single without children at home/single with children at home). Swedish Social Insurance Agency: MicroData for Analysis of the Social Insurance database: dates, main diagnosis and grade (full time or part time) of SA and DP. National Board of Health and Welfare: National Patient Register (dates and diagnoses for inpatient and specialised outpatient healthcare), Cause of Death Register (year of death). Individuals with back pain were followed prospectively for 12 months from the date of the first inpatient stay or specialised outpatient healthcare event for back pain in 2010 (index date, T0). The matched references were also followed for 12 months after the index date. Individuals were censored at the year of death if that occurred before the end of the 12-month follow-up. Individuals with at least one visit to inpatient or specialised outpatient healthcare in the 12 months before T0 for other diagnoses than M54 were defined as having multimorbidity, except for healthcare with uncomplicated delivery (O80) and burn-out (Z73.0).

Outcomes

Information on long-term SA (SA spells>14 days) and on DP were used to calculate the number of SA/DP net days during the 12 months from T0 and forward. All people living in Sweden, aged 16 years or above, with income from work or unemployment benefits, whose work capacity is reduced due to disease or injury can claim SA benefits. Day 1 is a waiting day, with 100% loss of income; from day 8, a medical certificate is required. The employer reimburses days 2–14, after which the Swedish Social Insurance Agency steps in. For individuals on unemployment benefits, the Swedish Social Insurance Agency reimburses SA benefits from day 2.21 In order not to introduce bias in relation to availability of SA data and employment status, only long-term SA spells >14 days were included in the analyses. DP can be granted to people aged 19–64 years and living in Sweden, even if not having any income, if their work capacity is reduced long term or permanently due to disease or injury.21 The regular age for old-age pension was 65 years in 2012. In Sweden, both SA and DP can be granted for full time (100%) or part time (75%, 50% or 25%) of ordinary work hours.21 This means that it is possible to have both partial SA and DP at the same time. Therefore, we calculated number of net days, for example, two absence days at 50% were combined into one net day. As a SA-spell could go on for years before DP was granted, long-term SA and DP days were combined (hereinafter, referred to as SA/DP). The societal costs related to productivity losses (hereinafter referred to as productivity losses) for people with back pain and for the reference group were estimated using the human capital approach.22 23 Productivity losses were estimated by multiplying the percentage of work time lost due to SA/DP per year by the age-adjusted mean annual income (451 664 Swedish kronor (SEK)24) for each individual, including social security contributions from employers (31.42%).25 The income was inflated to 2018 prices, using a harmonised index for consumer prices.26 To increase comparability, these data were converted from SEK to € at 2018 values (10.2567 SEK=€1).

Analyses

Descriptive analyses were conducted for the sociodemographic and multimorbidity characteristics, as well as to estimate the mean number of SA/DP days and productivity losses during the 12 months following the index date T0, for both the patients with back pain and the reference group. Since SA/DP is associated with a variety of sociodemographic factors,27–31 analyses of SA/DP were stratified based on the following sociodemographic variables: sex, age, type of living area, country of birth, educational level, occupational group and family situation. In addition, SA/DP during the 12-month follow-up was estimated for each of the following six different multimorbidity diagnostic groups: other musculoskeletal disorder (other M than M54), depressive disorder (F32–F34), other mental disorders (other F and Z73.0), neoplasms (C00–D48), diseases of the circulatory system (I00–I99) and other (all others, excluding E10–E14, Z73.0 and O80). The Pearson’s χ2 test was used to explore possible differences in the distribution of demographic and multimorbidity characteristics between the back pain and the reference groups (between-group comparison, see table 1).32
Table 1

Sociodemographic characteristics and multimorbidity of the cohort of people aged 19–60 years with specialised healthcare for back pain (n=23 176) and their matched references (n=115 880).

Back pain groupReference groupP value from Pearson’s χ2 test)
n (%)n (%)
Sexn.a.
 Women12 161 (52.47)60 805 (52.47)
 Men11 015 (47.53)55 075 (47.53)
Agen.a.
 19–29 years3909 (16.87)19 545 (16.87)
 30–39 years5386 (23.24)26 930 (23.24)
 40–49 years6870 (29.64)34 350 (29.64)
 50–60 years7011 (30.25)35 055 (30.25)
Educational level<0.0001
 Elementary school*4344 (18.74)16 710 (14.42)
 High school11 957 (51.59)55 509 (47.90)
 University/college6875 (29.66)43 661 (37.68)
Type of living arean.a.
 Big cities10 050 (43.36)50 250 (43.36)
 Medium-sized cities7530 (32.49)37 650 (32.49)
 Rural areas5596 (24.15)27 980 (24.15)
Country of birthn.a.
 Sweden18 311 (79.01)91 555 (79.01)
 Nordic countries659 (2.84)3295 (2.84)
 (except Sweden)
 EU 25 (excluding Nordic countries)541 (2.33)2705 (2.33)
 Rest of the world3665 (15.81)18 325 (15.81)
Occupational group<0.0001
 White collar7295 (31.48)43 161 (37.25)
 Blue collar12 603 (54.38)57 925 (49.99)
 Missing3278 (14.14)14 794 (12.77)
Family situation<0.0001
 Married/cohabitant without children at home2775 (11.97)13 422 (11.58)
 Married/cohabitant with children at home9442 (40.74)48 789 (42.10)
 Single without children at home8575 (37)44 223 (38.16)
 Single with children at home2384 (10.29)9446 (8.15)
DP at index daten.a.
 M54221375
 Other M8401762
 F or Z749573392
 Other9883083
Inpatient or specialised outpatient healthcare for different diagnoses in the 12 preceding months <0.0001
 Back pain (M54)23 176 (100)0 (0)
 Other musculoskeletal disorders (other M)9770 (42.15)21 483 (18.53)
 Depressive disorder (F32–F34)1875 (8.09)4680 (4.04)
 Other mental disorders (other F†)4130 (17.82)11 103 (9.58)
 Neoplasms (C00–D48)3806 (16.42)1458 (12.59)
 Diseases of the circulatory system (I00–I99)3668 (15.83)11 586 (10.01)
 Other‡21 787 (94.01)98 984 (85.42)

Those in the reference group were matched on age, sex, type of living area and country of birth with the back-pain group. Therefore, it was not relevant to report p values for these variables (p values not shown in the table). Instead, p values are shown for the variables that were not used for matching. Between-group comparisons were performed using the Pearson’s χ2 test; that is, in this comparison, we explore the possible differences in the distribution of demographic and multimorbidity characteristics between the back-pain and the reference groups.

*Includes missing information on level of educational level, for back pain: 129 individuals and 997 individuals in the reference group.

†Including Z73.0.

‡Excluding missing data, Z73.0 and O80.

DP, disability pension; n.a., not applicable.

Sociodemographic characteristics and multimorbidity of the cohort of people aged 19–60 years with specialised healthcare for back pain (n=23 176) and their matched references (n=115 880). Those in the reference group were matched on age, sex, type of living area and country of birth with the back-pain group. Therefore, it was not relevant to report p values for these variables (p values not shown in the table). Instead, p values are shown for the variables that were not used for matching. Between-group comparisons were performed using the Pearson’s χ2 test; that is, in this comparison, we explore the possible differences in the distribution of demographic and multimorbidity characteristics between the back-pain and the reference groups. *Includes missing information on level of educational level, for back pain: 129 individuals and 997 individuals in the reference group. †Including Z73.0. ‡Excluding missing data, Z73.0 and O80. DP, disability pension; n.a., not applicable. Another between-group comparison was performed to identify the difference of costs between the back-pain group and the references with regards to demographic, socioeconomic and multimorbidity characteristics; this comparison was made using a two-tailed t-test with unequal variances (statistical significance: α<0.0001). Two in-group comparisons were performed—one regarding differences in productivity losses between women and men in the back-pain group, and the other exploring the impact of multimorbidity on productivity losses, when already diagnosed with back pain. These comparisons were performed using a two-tailed t-test with unequal variances (statistical significance: α<0.0001).

Patient and public involvement

Patients and the public were not involved in this register-based study.

Results

In all, 23 176 individuals with back pain and 115 880 matched references were included in the analyses. A higher proportion of the individuals with back pain had lower educational level and blue collar occupations (table 1). Regarding multimorbidity, the cohort of patients with back pain had significantly higher proportions of people with other musculoskeletal disorders (42%) and mental disorders (26%) compared with the reference group (19% and 14%, respectively). The mean number of SA/DP days during the 12-month follow-up was 74 among the individuals with back pain and 29 among those in the reference group (table 2). The majority of individuals in both the back pain and the reference groups had no SA/DP days. Nonetheless, the back-pain group had a larger proportion of individuals with 15–249 SA/DP days during the 12 months following T0 (28%), compared with the reference group (9%; figure 1). In addition, the back-pain cohort had a higher proportion of individuals with ≥250 SA/DP days. In the back-pain cohort, 52% of the total net SA/DP days were with DP; the corresponding number was 70% in the reference group. The proportion among the patients with back pain of women and men with back pain in blue collar occupations was about the same: 54.09% and 54.70%, respectively. The corresponding proportions among the references were 50.18% and 49.77%, respectively.
Table 2

Mean number of sickness absence (SA)/disability pension (DP) net days and mean productivity losses per individual, among 23 176 people with incident back pain in 2010 and 115 880 matched references, in the 12 months after inclusion, for all those included, and in relation to sociodemographic characteristics and multimorbidity.

Mean SA/DP daysMean cost per person and year (€)T-test
DifferenceReferencesBack painReferencesBack pain(P value)
Sex
 Women863410 37641026274<0.0001
 Men6024723928964343<0.0001
Age
 19–29 years3612434314482895<0.0001
 30–39 years5115615318104343<0.0001
 40–49 years7327880732575550<0.0001
 50–60 years1125313 51263947118<0.0001
Educational level
 Elementary school1106813 27182045067<0.0001
 High school7729929034995791<0.0001
 University/college4614555016893861<0.0001
Type of living area
 Big cities6227748032574223<0.0001
 Medium-sized cities7829941034995912<0.0001
 Rural areas883310 61739816636<0.0001
Country of birth
 Sweden7126856631375429<0.0001
 Nordic countries (except Sweden)1105113 27161537118<0.0001
 EU 25 (excluding Nordic countries)8240989348265067<0.0001
 Rest of the world8139977247055067<0.0001
Occupational group
 White collar4011482613273499<0.0001
 Blue collar7724929028966394<0.0001
 Missing1389916 64911 9444705<0.0001
Family situation
 Married or cohabitant without children994111 94449476997<0.0001
 Married or cohabitant with children5917711820515067<0.0001
 Single without children833910 01447055308<0.0001
 Single with children863510 37642236153<0.0001
Inpatient or specialised outpatient healthcare for different diagnoses
 Depressive disorder (F32–F34)15511618 70013 9954705<0.0001
 Other mental disorders (other F)*14311417 25213 7543499<0.0001
 Neoplasms (C00–D48)1024512 30654296877<0.0001
 Diseases of the circulatory system (I00–I99)1257015 08184456636<0.0001
 Other†7732929038615429<0.0001
 No other diagnoses other than back pain (M54)22n.a.2654n.a.n.a.n.a.
All individuals
7429892834995429<0.0001

Inpatient or specialised outpatient healthcare for different diagnoses was defined in the 12 months before inclusion in the cohorts. The presence of depressive and other mental disorders, neoplasms, diseases of the circulatory system or other diseases was defined using International Statistical Classification of Diseases and Related Health Problems information from National Patient Register (secondary healthcare). For patients with back pain, these diagnoses were assumed to be in addition to the back pain diagnosis the patients had. Information for patients with back pain without any other diagnoses is also presented in this table (not relevant for the reference population).

*Including Z73.0.

†Excluding missing data, Z73.0 and O80.

n.a., not applicable.

Figure 1

Proportions (%) of patients with back pain and matched references, respectively, with different number of sickness absence (SA)/disability pension (DP) days in the 12 months following the diagnosis date.

Proportions (%) of patients with back pain and matched references, respectively, with different number of sickness absence (SA)/disability pension (DP) days in the 12 months following the diagnosis date. Mean number of sickness absence (SA)/disability pension (DP) net days and mean productivity losses per individual, among 23 176 people with incident back pain in 2010 and 115 880 matched references, in the 12 months after inclusion, for all those included, and in relation to sociodemographic characteristics and multimorbidity. Inpatient or specialised outpatient healthcare for different diagnoses was defined in the 12 months before inclusion in the cohorts. The presence of depressive and other mental disorders, neoplasms, diseases of the circulatory system or other diseases was defined using International Statistical Classification of Diseases and Related Health Problems information from National Patient Register (secondary healthcare). For patients with back pain, these diagnoses were assumed to be in addition to the back pain diagnosis the patients had. Information for patients with back pain without any other diagnoses is also presented in this table (not relevant for the reference population). *Including Z73.0. †Excluding missing data, Z73.0 and O80. n.a., not applicable. The productivity loss per individual with back pain was €8928, compared with €3499 (p<0.0001) in the reference group. Thus, having had specialised healthcare for a back pain diagnosis meant additional productivity losses of €5429 (p<0.0001) during the 12 months following a first visit to specialised healthcare for back pain, compared with the references. An in-group comparison (not shown in table 2), testing the differences of costs between women and men in the back-pain group, revealed that costs for back pain were significantly higher among women €10 376 than among men €7239 (p<0.0001). The number of SA/DP days and thus, productivity losses, varied between the back-pain cohort and the references regarding both sociodemographic characteristics and multimorbidity (table 2, figure 2). The disease groups that accounted for the highest numbers of SA/DP days for both the back pain and the reference groups were depressive disorder and other mental disorders. Individuals with both back pain and depressive disorder had €4705 higher costs compared with those in the reference group.
Figure 2

Mean productivity losses for the patients with back pain and the references, respectively, among all and for those with various types of multimorbidity. The coloured bars show the mean amount of productivity loss for each disease category.

Mean productivity losses for the patients with back pain and the references, respectively, among all and for those with various types of multimorbidity. The coloured bars show the mean amount of productivity loss for each disease category. Within the back-pain group, people with both back pain and depressive disorder or other mental disorders, in general, had more SA/DP days and productivity losses than those patients in the back-pain group with no other diagnoses than back pain (p<0.0001; table 2). Figure 2 shows the mean productivity loss for both the back-pain group and the reference group, as well as for people with multimorbidity, also showing what diagnoses categories that accounted for most productivity losses. The proportion of mean productivity losses (as seen in figure 2) was evenly distributed between the diagnostic categories. However, when we subgrouped, based on depressive disorder and other mental disorders, the results were skewed, with about 50%–70% of the costs attributed to F diagnoses (data not shown in figure 2). The largest differences in costs between the back-pain group and the reference group occurred among individuals with both back pain and neoplasms (C00–D48); they had €6877 higher costs compared with their references (p<0.0001).

Discussion

In this explorative prospective cohort study based on data obtained from nationwide registers in Sweden, we found that individuals of working age with a first specialist healthcare visit for back pain had 45 more SA/DP days during the 12-month follow-up period, compared with the matched reference group drawn from the general population of Sweden. This translates into excess annual productivity losses of €5429/individual. However, not all had SA/DP in the two groups; in the back-pain group, 42% and in the reference group 15% had at least some long-term SA/DP during the 12-month follow-up period. Like previous studies based on selective survey samples from the UK and USA,30 31 this nationwide register-based study also found a difference between the back-pain group and the reference group regarding their attained educational level and occupation. Those in the back-pain cohort generally had a lower educational level compared with the matched references. In addition, the proportion of blue collar workers was significantly higher in the back-pain cohort compared with the references. One of the suggested mechanisms for the correlation between low education and back pain is that healthcare tends to be unavailable or not adequately targeted to people with low education and back pain.33 However, this inequality is not as present in Sweden as in many other healthcare systems.34 Occupational and behavioural risk factors have also been suggested as possible underlying mechanisms.33 Nonetheless, none of these mechanisms can fully explain this correlation and low educational level is an important risk factor on its own.33 With regards to occupation, individuals in manual occupations are at higher risk of developing severe back pain than individuals in white collar work.30 31 Being exposed to physical workload can be associated with disabling back pain, which white collar occupations are not.30 31 It is also plausible that individuals with back pain who perform manual work struggle to return to physically demanding work tasks before quite ready for that. When comparing the SA/DP net days and productivity losses between the group of patients with back pain and that of references, the mean productivity losses/year per individual with back pain was €5429 higher than for the references. While we measured only productivity loss costs in this study, not medication, nor healthcare costs, it is known that approximately 84% of the total costs for back pain are attributed to productivity losses.17 In a recent cost-of-illness study of individuals with low back pain in the Västra Götaland region in Sweden,35 the mean cost per individuals following one episode of low back pain was €2753. In an in-group comparison, we explored how gender correlated with productivity losses from back pain, since previous studies have shown that women tend to have higher rates of both long-term SA and DP.13 36 This finding from previous studies is also in line with our study, where women with back pain had a mean productivity loss €1931 higher than men with back pain. The reasons for women having more SA/DP are not fully understood.13 36 Generally, more women report back pain.2 Still, many jobs are structured, also including detailed work tasks, with the male body and strength as the norm.37 38 In Sweden, the employment frequency of women is very high, also in higher ages, and a large rate of the women work in blue collar occupations—occupations that often involve high physical workloads, for example, as auxiliary nurses. Further, in another in-group comparison, we explored the associations between multimorbidity and productivity loss among individuals with back pain. Individuals with back pain, with at least one other diagnosis, in general had greater productivity losses than individuals that only had a back-pain diagnose. These findings were consistent with the results from two previous studies on multimorbidity and SA.14 39 Moreover, individuals with back pain with a depressive disorder or other mental disorder had the highest mean productivity losses in the back-pain cohort. It is well established that depression is a risk factor for developing chronic back pain.29 40 Dorner et al point out the importance of proper diagnostics and treatment of both conditions in order to avoid long-term SA and, in worst cases, DP.39

Strengths and limitations

The main strengths of this study are the use of data from high-quality nationwide registers, the prospective cohort design and the use of a large cohort with matched references, allowing subgroup analysis based on a wide variety of sociodemographic and multimorbidity aspects. The complete dataset enabled the inclusion of all people with a visit to specialist healthcare for a back-pain diagnosis in 2010, thereby eliminating selection bias. Another benefit of having access to the nationwide registers is the possibility to establish a matched reference group. The matched reference group allowed us to demonstrate the excess productivity loss in the population with back pain in Sweden. Another strength was that net days of SA and DP could be calculated. The use of administrative data regarding all SA spells>14 days and all DP days41 allowed detailed calculations of the productivity losses without recall bias. We did not have information about primary healthcare visits, which can be seen as a limitation, as we missed people with less severe back pain and as a strength as we had the more severe cases. Since we lack primary healthcare data, it is possible that some of the individuals in the reference group could have had back pain, however, not severe enough to require specialised, secondary healthcare. Another limitation is the lack of information on SA spells ≤14 days. Thus, the cost estimates are conservative and likely underestimate the number of SA days, as most SA spells for individuals with back pain would probably be shorter than 14 days.42 Another limitation is the lack of information on the severity of back pain and other morbidities. The difference between mild and severe symptoms of back pain could play a major role when predicting the productivity losses from back pain. This is the first study on productivity losses where nationwide register data have been used. Assumptions due to incomplete data play a lesser role in the analysis when the dataset provides a complete overview of the population. Thus, descriptive analyses were used to analyse the occurrence of SA/DP days in the groups. The data have been stratified in order to evaluate SA/DP in different socioeconomic and multimorbidity groups. We believe that these results provide valuable insight to the productivity losses of back pain in Sweden. Nevertheless, an important limitation to the descriptive analysis is the risk of confounders effects. Therefore, future research should adjust for potential confounders in order to improve the accuracy of our results.

Conclusion

We found that individuals with back pain had substantially higher productivity losses when compared with matched references without back pain; their productivity losses were 2.6 times higher, which amounts to €5429 more per year and individual. This can indicate that more needs to be done in order to help individuals with back pain to remain in or return to work.
  33 in total

1.  Predictors of low back pain onset in a prospective British study.

Authors:  C Power; J Frank; C Hertzman; G Schierhout; L Li
Journal:  Am J Public Health       Date:  2001-10       Impact factor: 9.308

Review 2.  Non-specific low back pain.

Authors:  Federico Balagué; Anne F Mannion; Ferran Pellisé; Christine Cedraschi
Journal:  Lancet       Date:  2011-10-06       Impact factor: 79.321

Review 3.  Swedish Council on Technology Assessment in Health Care (SBU). Chapter 1. Aim, background, key concepts, regulations, and current statistics.

Authors:  Kristina Alexanderson; Anders Norlund
Journal:  Scand J Public Health Suppl       Date:  2004       Impact factor: 3.021

4.  Sickness absence because of musculoskeletal diagnoses and risk of all-cause and cause-specific mortality: a nationwide Swedish cohort study.

Authors:  Catarina Jansson; Ellenor Mittendorfer-Rutz; Kristina Alexanderson
Journal:  Pain       Date:  2012-03-14       Impact factor: 6.961

Review 5.  Incidence and risk factors for first-time incident low back pain: a systematic review and meta-analysis.

Authors:  Jeffrey B Taylor; Adam P Goode; Steven Z George; Chad E Cook
Journal:  Spine J       Date:  2014-01-23       Impact factor: 4.166

6.  Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting.

Authors:  Mattias Ekman; Sven Jönhagen; Elke Hunsche; Linus Jönsson
Journal:  Spine (Phila Pa 1976)       Date:  2005-08-01       Impact factor: 3.468

7.  Sickness absence with low-back, shoulder, or neck diagnoses: an 11-year follow-up regarding gender differences in sickness absence and disability pension.

Authors:  Kristina A E Alexanderson; Karin E Borg; Gunnel K E Hensing
Journal:  Work       Date:  2005

8.  Cost of low back pain: results from a national register study in Sweden.

Authors:  Gylfi Olafsson; Emma Jonsson; Peter Fritzell; Olle Hägg; Fredrik Borgström
Journal:  Eur Spine J       Date:  2018-08-28       Impact factor: 3.134

9.  Does life course socio-economic position influence chronic disabling pain in older adults? A general population study.

Authors:  Rosie J Lacey; John Belcher; Peter R Croft
Journal:  Eur J Public Health       Date:  2012-08-08       Impact factor: 3.367

10.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.

Authors:  Jonas F Ludvigsson; Petra Otterblad-Olausson; Birgitta U Pettersson; Anders Ekbom
Journal:  Eur J Epidemiol       Date:  2009-06-06       Impact factor: 8.082

View more
  3 in total

1.  Occupational recovery of Dutch workers with low back pain.

Authors:  I Brus; E Speklé; P P Kuijer; M Hardenberg; P Coenen
Journal:  Occup Med (Lond)       Date:  2022-10-18       Impact factor: 5.629

2.  Psychosocial Working Conditions and Subsequent Sickness Absence-Effects of Pain and Common Mental Disorders in a Population-Based Swedish Twin Sample.

Authors:  Annina Ropponen; Mo Wang; Kristin Farrants; Jurgita Narusyte; Pia Svedberg
Journal:  J Occup Environ Med       Date:  2022-02-01       Impact factor: 2.306

3.  A 7-Year Study of the Durability of Improvements in Pain, Physical Function, and Work Productivity After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy.

Authors:  Wendy C King; Amanda S Hinerman; Gretchen E White
Journal:  JAMA Netw Open       Date:  2022-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.